Regeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including mā¦ read more
Healthcare
Biotechnology
35 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$762.63
Price+3.29%
$24.29
1Y
Price
Market Cap
$78.568b
Large
Price/Earnings 3y Avg5y Avg
16.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+26.8%
EBITDA Margin+20.2%
Net Profit Margin+23.5%
Free Cash Flow Margin+26.8%
EBITDA Margin+20.2%
Net Profit Margin+23.5%
Free Cash Flow MarginRevenue
$15.535b
+4.0%
1y CAGR+4.4%
3y CAGR+5.3%
5y CAGREarnings
$4.329b
-1.8%
1y CAGR+4.0%
3y CAGR+0.8%
5y CAGREPS
$40.43
-1.1%
1y CAGR+5.8%
3y CAGR+2.1%
5y CAGRBook Value
$31.710k
$41.730k
Assets$10.020k
Liabilities$1.990k
DebtDebt to Assets
4.8%
0.5x
Debt to EBITDAFree Cash Flow
$3.522b
+1.8%
1y CAGR+4.4%
3y CAGR-1.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company